Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia

Br J Cancer. 2017 Jun 27;117(1):136-143. doi: 10.1038/bjc.2017.148. Epub 2017 May 18.

Abstract

Background: Long-standing ulcerative colitis (UC) leading to colorectal cancer (CRC) is one of the most serious and life-threatening consequences acknowledged globally. Ulcerative colitis-associated colorectal carcinogenesis showed distinct molecular alterations when compared with sporadic colorectal carcinoma.

Methods: Targeted sequencing of 409 genes in tissue samples of 18 long-standing UC subjects at high risk of colorectal carcinoma (UCHR) was performed to identify somatic driver mutations, which may be involved in the molecular changes during the transformation of non-dysplastic mucosa to high-grade dysplasia. Findings from the study are also compared with previously published genome wide and exome sequencing data in inflammatory bowel disease-associated and sporadic colorectal carcinoma.

Results: Next-generation sequencing analysis identified 1107 mutations in 275 genes in UCHR subjects. In addition to TP53 (17%) and KRAS (22%) mutations, recurrent mutations in APC (33%), ACVR2A (61%), ARID1A (44%), RAF1 (39%) and MTOR (61%) were observed in UCHR subjects. In addition, APC, FGFR3, FGFR2 and PIK3CA driver mutations were identified in UCHR subjects. Recurrent mutations in ARID1A (44%), SMARCA4 (17%), MLL2 (44%), MLL3 (67%), SETD2 (17%) and TET2 (50%) genes involved in histone modification and chromatin remodelling were identified in UCHR subjects.

Conclusions: Our study identifies new oncogenic driver mutations which may be involved in the transition of non-dysplastic cells to dysplastic phenotype in the subjects with long-standing UC with high risk of progression into colorectal neoplasia.

MeSH terms

  • Activin Receptors, Type II / genetics
  • Adenomatous Polyposis Coli Protein / genetics
  • Class I Phosphatidylinositol 3-Kinases
  • Colitis, Ulcerative / complications*
  • Colorectal Neoplasms / etiology
  • Colorectal Neoplasms / genetics*
  • DNA Helicases / genetics
  • DNA-Binding Proteins / genetics
  • Dioxygenases
  • Histone-Lysine N-Methyltransferase / genetics
  • Humans
  • Mutation
  • Mutation, Missense
  • Neoplasm Proteins / genetics
  • Nuclear Proteins / genetics
  • Phosphatidylinositol 3-Kinases / genetics
  • Polymerase Chain Reaction
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins c-raf / genetics
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Receptor, Fibroblast Growth Factor, Type 2 / genetics
  • Receptor, Fibroblast Growth Factor, Type 3 / genetics
  • Sequence Analysis, DNA
  • TOR Serine-Threonine Kinases / genetics
  • Transcription Factors / genetics
  • Tumor Suppressor Protein p53 / genetics

Substances

  • APC protein, human
  • ARID1A protein, human
  • Adenomatous Polyposis Coli Protein
  • DNA-Binding Proteins
  • KMT2C protein, human
  • KMT2D protein, human
  • KRAS protein, human
  • Neoplasm Proteins
  • Nuclear Proteins
  • Proto-Oncogene Proteins
  • TP53 protein, human
  • Transcription Factors
  • Tumor Suppressor Protein p53
  • Dioxygenases
  • TET2 protein, human
  • Histone-Lysine N-Methyltransferase
  • SETD2 protein, human
  • MTOR protein, human
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CA protein, human
  • FGFR2 protein, human
  • FGFR3 protein, human
  • Receptor, Fibroblast Growth Factor, Type 2
  • Receptor, Fibroblast Growth Factor, Type 3
  • Proto-Oncogene Proteins c-raf
  • TOR Serine-Threonine Kinases
  • Activin Receptors, Type II
  • activin receptor type II-A
  • SMARCA4 protein, human
  • DNA Helicases
  • Proto-Oncogene Proteins p21(ras)